

**Original Article****ASSESSMENT OF THE THERAPEUTIC EFFICACY OF TWO ARTEMISININ-BASED COMBINATIONS IN THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA AMONG CHILDREN UNDER 5 YEARS IN FOUR DISTRICT HOSPITALS IN SIERRA LEONE****Sahr F<sup>1\*</sup>, Smith S. J<sup>2</sup>, Kamara A<sup>2</sup>, Warsame M<sup>3</sup>, Sillah J<sup>4</sup> and Swarray A<sup>5</sup>.**

<sup>1</sup>College of Medicine and Allied Health Sciences, University of Sierra Leone. <sup>2</sup>National Malaria Control Programme, Ministry of Health and Sanitation. <sup>3</sup>Global Malaria Programme, World Health Organization, Geneva, Switzerland. <sup>4</sup>World Health Organization Country Office, Sierra Leone. <sup>5</sup>Connaught Hospital Central Laboratory, Ministry of Health and Sanitation.

**Abstract**

*Plasmodium falciparum* has developed resistance to almost every class of antimalarial compounds. As a result of this, the World Health Organization has recommended artemisinin-based combination therapy as first line treatment for *P. falciparum* malaria. There is however need for the continuous monitoring of the efficacy of these antimalarials in order to provide timely information on trends of the emergence of resistant strains. We assessed the therapeutic efficacy of oral artesunate – amodiaquine and artemether-lumefantrine combinations in the treatment of uncomplicated *P. falciparum* malaria in four District Hospitals in Sierra Leone. A total of 320 children under five years participated in the study sites (Kenema, Rokupa, Bo and Makeni). Oral Artesunate-amodiaquine combination was administered to participants in Kenema and Rokupa whilst Artemether-lumefantrine combination was administered to participants in Bo and Makeni. The new WHO Protocol for recruitment of participants in therapeutic efficacy trials in high transmission zones was adopted for the study with filter paper blood samples taken from each participant on days 0 and 28 to distinguish between treatment failure and new infection. When uncorrected for PCR analysis, 96% (95% CI: 90.2 – 98.9) and 100% (95% CI: 63.1 – 100) responses were obtained in Kenema and Bo respectively with Artesunate-amodiaquine combination whilst 94.3% (CI 95 : 88.1 – 97.9) and 100% (95% CI: 96.5 – 100) were obtained with Artemether-lumefantrine combination in Bo and Makeni respectively. When corrected for PCR on the other hand, a 100% (95% CI) Adequate Clinical and Parasitological Response was obtained for the two drugs in all four study sites. Results from this study indicate that both Artesunate-amodiaquine and Artemether-lumefantrine combinations remain highly efficacious in Sierra Leone with presently no observed emergence of resistant strains to both drugs.

**Keywords:****Artemisinin-based combination, uncomplicated falciparum malaria, children, Sierra Leone****Introduction**

Malaria remains a major cause of morbidity and mortality and is estimated to cause 881,000 deaths globally per year. Sub-Saharan Africa is disproportionately affected, suffering 91% of global malaria deaths with 88% occurring in children under 5 years of age (WHO 2008).

Recent reports however indicate that in almost 40% of the world's malaria endemic countries reported cases have dropped by half over the last decade (Johnson et al 2010). *Plasmodium falciparum*, which causes the most life-threatening malaria has developed resistance

to almost every class of antimalarial compound (WHO 2010), as a result of which the

\*Corresponding author: E-mail: [fsahr@yahoo.com](mailto:fsahr@yahoo.com)

World Health Organization has recommended artemisinin-based combination therapy (ACT) as first-line treatment of *P. falciparum* malaria. ACT is the combination of artemisinin or an artemisinin derivative (artesunate, artemether, dehydroartemisinin) and a partner drug (amodiaquine, mefloquine, piperazine, lumifantrine, sulphadoxine, pyremethamine) having a markedly longer half life in the blood stream than artemisinin.

Hence, the rationale for ACT is that the artemisinin precipitously reduces the parasitaemia, and the less potent but longer-acting partner drug kills any residual parasites over 1 – 2 weeks (Fairhurst et al 2012). Recent reports suggest an impaired parasite response to artemisinin monotherapy in the Cambodia-Thailand border region (Dondorp et al 2009; Anderson et al 2010). Here in Sierra Leone treatment failures with artemisinin monotherapy have also been reported (Sahr et al 2001).

There is no available data on the efficacy of ACTs in Sierra Leone although limited data does suggest that failed treatment to these drugs is rare (Sahr et al 2009). No nationwide survey has been attempted to monitor the efficacy of the ACTs in Sierra Leone since their introduction in 2008. The introduction of a new antimalarial drug requires continuous monitoring in order to provide timely information on the emergence of resistant strains. The objective of this study was to assess the therapeutic efficacy of oral Artesunate-amodiaquine and oral Artemether – lumifantrine combination therapies in the treatment of uncomplicated *P. falciparum* malaria and corrected for PCR analysis in children under 5 years in four (4) District hospitals in Sierra Leone.

## Patients and Methods

### a. Study design

This was a randomized efficacy study of oral artesunate-amodiaquine and oral artemether – lumifantrine combination therapies for the treatment of uncomplicated *P. falciparum* malaria in children under 5 years, conducted according to the principles of Good Clinical Practice. Study sites were randomly assigned to 1 of 2 study drugs: (1) Oral Artesunate –

amodiaquine combination therapy or (2) Oral Artemether – lumifantrine combination therapy, administered according to the recommendation of the World Health Organization.

The study was approved by the Ethics and Research Committee of the Ministry of Health and Sanitation.

### b. Data collection

Data was collected in four Government Hospitals: Kenema, Rokupa, Bo and Makeni. All four Hospitals are supervised by Medical Doctors with established Under-five Clinics and Laboratories. Only children below five years were enrolled in the study. The new WHO Protocol (WHO 2008) for recruitment of participants in therapeutic efficacy trials in high transmission zones was adopted. Filter Paper blood were taken from each participant on Days 0 and 28 for PCR analysis where indicated to distinguish between parasitological failure and new infection. Inclusion criteria used in the study were: children below 5 years, axillary temperature  $\geq 37.5^{\circ}\text{C}$ , mono-infection with *Plasmodium falciparum*, parasitaemia  $\geq 1000$  parasites/ $\mu\text{l}$  of blood, and informed consent from accompanying parents or guardians.

Participants with severe or complicated malaria according to the WHO classification (WHO 1996) were excluded from the study and treated with parenteral artemisinin. The two study drugs were provided by WHO and passed the general counterfeit test of the Pharmacy Board of the Ministry of Health and Sanitation.

Both artesunate-amodiaquine and artemether – lumifantrine were administered orally under the direct supervision of a nurse. Participants were followed-up on Days 1, 2, 3, 7, 14, 21 and 28 during which their general conditions were assessed and blood smears prepared for the demonstration and quantification of *Plasmodium falciparum* parasitaemia. Axillary temperature was recorded for each participant on all follow-up days and the response to treatment recorded according to the WHO recommendation (WHO 1996): Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF) and Late Treatment Failure (LTF). Briefly, ACPR was defined as absence of parasitaemia on day 14

irrespective of axillary temperature  $< 37.5^{\circ}\text{C}$  and irrespective of parasitaemia without previously meeting any of the criteria of ETF. Therapeutic response was classified as ETF if the subject developed one of the following conditions during the first three days of follow-up:

- Axillary temperature  $\geq 37.5^{\circ}\text{C}$  on Day 2 with parasitaemia greater than that on Day 0.
- Axillary temperature  $\geq 37.5^{\circ}\text{C}$  on Day 3 in the presence of parasitaemia.
- Parasitaemia on Day 3  $\geq 25\%$  of count on Day 0.

Therapeutic response was classified as LTF if a participant's axillary temperature was  $\geq 37.5^{\circ}\text{C}$  in the presence of parasitaemia on any day from Day 4 to Day 14 without previously meeting the criteria of ETF.

### Ethical Clearance

Ethical clearance for the conduct of the study was obtained from the Ethics and Research Committee of the Ministry of Health and Sanitation.

### Result

A total of 320 children below 5 years were enrolled in the study. Of these, 101 were from Kenema, 8 from Rokupa, 106 from Bo and 105 from Makeni. Artesunate-

amodiaquine combined therapy was administered to participants in Kenema and Rokupa, while artemether – lumefantrine combined therapy was administered to participants in Bo and Makeni. Table I summarizes the therapeutic efficacy of the two study drugs amongst the 320 participants from the four study sites without PCR analysis of the filter paper blood to distinguish between true parasitological failure and re-infection. From Table I, 96% and 100% Adequate Clinical and Parasitological Responses were observed with Artesunate-amodiaquine combined therapy in Kenema and Rokupa respectively (95% CI). For Artemether-lumefantrine combined therapy on the other hand, 94.3% and 100% Clinical and Parasitological Responses were observed in Bo and Makeni respectively (95% CI). After PCR analysis of the filter blood samples of the participants with apparent Clinical and Parasitological failure in Kenema for artesunate-amodiaquine and Bo for artemether-lumefantrine combined therapies, a 100% Adequate Clinical and Parasitological Response was obtained for the two study drugs in the four study sites (Table II).

**Table 1. Therapeutic efficacy of artesunate + amodiaquine in two sites and artemether+lumefantrine in two sites, Sierra Leone.**

Treatment outcome	Artesunate + amodiaquine		Artemether + lumefantrine	
	Kenema (n = 101)	Rokupa (n = 8)	Bo (n = 106)	Makeni (n = 105)
% Early Treatment Failure (95% CI)	0.0 (0.0-3.6)	0.0 (0.0 – 36.9)	0.0 (0.0 – 3.4)	0.0 (0.0 – 3.5)
% Late Treatment Failure (95% CI)	1.0 (0.0 – 5.4)	0.0 (0.0 – 36.9)	0.9 (0.0 – 5.1)	0.0 (0.0 – 3.5)
% Late Parasitological Failure (95% CI)	3.0 (0.6 – 8.4)	0.0 (0.0 – 36.9)	4.7 ( 1.5 – 10.7)	0.0 (0.0 – 3.5)
% Adequate Clinical & Parasitological Response (95% CI)	96.0 (90.2 – 98.9)	100 (63.1 – 100)	94.4 (88.1 – 97.9)	100 (96.5 – 100)
Kaplan-Meier Cumulative Treatment Failure Rate	0.0	0.0	5.6 (2.6 – 12.1)	0.0

PCR uncorrected responses

.

**Table 2. Therapeutic efficacy of artesunate+amodiaquine in four sites and artemether+lumefantrine in four sites, Sierral Leone.**

PCR Corrected Response

Treatment outcome	Artesunate+amodiaquine		Artemether+lumefantrine	
	Kenema (n=101)	Rokupa (n=8)	BO (n=106)	Makeni (n=105)
% Early Treatment failure (95% CI)	0.0 (0.0-3.7)	0.0 (0.0-36.9)	0.0 (0.0-3.6)	0.0 (0.0-3.5)
% Late Clinical Failure(95% CI)	0.0 (0.0-3.7)	0.0 (0.0-36.9)	0.0 (0.0-3.6)	0.0 (0.0-3.5)
LateParasitologicalFailure(95 % CI)	0.0 (0.0-3.7)	0.0 (0.0-36.9)	0.0 (0.0-3.6)	0.0 (0.0-3.5)
% Adequate Clinical & Parasitological response(95% CI)	100 (96.3-100)	100 (63.1-100)	100 (96.4-100)	100 (96.5-100)
Kaplan-MeierCumulative Treatment Failure Rate	0.0	0.0	0.0	0.0

### Discussion

Child mortality from *P. falciparum* malaria increased significantly in the 1980s when chloroquine-resistant parasites arrived in Sub-Saharan Africa (Trape 2001; Dondrop et al 2010). As the parasite developed resistance to more antimalarial drugs, the World Health Organization recommended ACTs as first-line treatment for uncomplicated *P. falciparum* malaria. Although the most common ACTs are Artemether-mefloquine and Artemether-lumefantrine (WHO 2006), the Ministry of Health and Sanitation in Sierra Leone recommend Oral Artesunate-amodiaquine and oral artemether-lumefantrine for the treatment of uncomplicated *P. falciparum* malaria.

When the results are not corrected for with PCR analysis, a 3% and 4.7% Late Parasitological failures were observed in Kenema and Bo respectively. With PCR corrected responses on the other hand, results suggest that both oral Artesunate-amodiaquine and oral artemether-lumefantrine combination therapies are highly efficacious in the treatment of uncomplicated *P. falciparum*

malaria as evidenced by the 100% ACPR in all four study sites.

Although there are no available reports on treatment failures with ACTs in Sierra Leone, a number of research groups in South -East Asia have started detecting the first signs of artemisinin resistant which may threaten to compromise the efficacy of ACTs (Fairhurst 2012). Recent clinical and molecular studies suggest the emergence of ACT-resistant *Plasmodium falciparum* in the Cambodia-Thailand border area, were the standard ACT is Artesunate-mefloquine combination therapy (Wongsrichanalua et al 2000). They suggested that the treatment failures reported might be due to mefloquine used as monotherapy in the treatment of *P. falciparum* malaria long before the introduction of ACTs.

Sahr et al (2001) reported 4 cases of apparent treatment failure with Artesunate use as monotherapy. Using the WHO criteria for the classification of treatment outcome with antimalarial drugs, all four treatment failures were reported as ETFs. In a therapeutic efficacy study conducted in Ghana by Abuaku et al 2012 to evaluate Artemether-lumefantrine in the treatment of uncomplicated malaria in children under 5

years in three ecological zones, they reported an overall pre-corrected cure rate of 95.4% (95% CI: 90.3 – 98.0). These results are similar to our PCR uncorrected response of 96.0% (95% CI) and 94.3% (95% CI) obtained in Kenema and Bo respectively. They concluded from their study that Artemether-lumefantrine remains efficacious in Ghana for the treatment of uncomplicated malaria. Post corrected PCR cure rates in our study demonstrated a 100% ACPR (95% CI) in all four study sites on Day 28. This shows that both oral Artesunate-amodiaquine and artemether-lumefantrine are highly efficacious in the treatment of uncomplicated *P. falciparum* malaria in Sierra Leone and emergences of resistant strains of the parasite to the two drugs are yet to appear. It is therefore recommended that the Ministry of Health and Sanitation undertakes continuous monitoring of the efficacy of these Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Siedlein L, 2010. Artemisinin Resisitance: Curent Status and Scenarios for containment, Nat Rev Microbiol **8**:272.

Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, an SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, 2009. Artemisinin resistance in *Plasmodium flaciparum* malaria. N Engl J Med **361**: 455-467.

Elhassan IM, Satti GH, Ali EA, Fadul I, EIKhalifa AA, Abederirahim AM, Ming C and Theander TG (1993). The Efficacy of Artenether in the Treatment of *Plasmodium falciparum* malaria in Sudan. Soc. Trans R Soc Trop Med Hyg. **87**:685-686.

Johnson E, Cibulskis R, Steketee R, 2010. Malaria Funding & Resource Utilization : The First Decade of Roll Back Malaria. Geneva , Switzaerland: Roll Back Malaria.

drugs so that timely information on the emergency of any treatment failures could be reported.

## References

Abuaku B, Duah N, Quaye C, Quashie N, and Koram K, 2012..

<http://www.malariajournal.com/content/11/51/P107>

Anderson TJ, Nair S, Nkhoma S, Nkhoma S, Williams JT, Imwong M, Yi P, Socheat D, Das D, Chotivanich K Day NP, White NJ, Dondorp AM, 2010. High heritability of Malaria Parasite clearance rate indicates a genetic basis for artemisinin resistance in Western Cambodia. J Infect Dis **201**: 1326-1330.

Sahr F. Willoughby VR, Gbakima AA and Backarie MJ (2001). Apparent Drug Failure following Artesunate Treatment of *Plasmodium falciparum* Malaria in Freetown, Sierra Leone Four Case Reports. Annal Trop Med Paras. **95**:445-449

World Health Organization (2003). Assessment of Therapeutic Efficacy of Antimalaria Drugs for Uncomplicated *P. falciparum* Malaria in Areas with Intense Transmission. WHO Geneva: Pp:5-12

WHO, 2010. Global Report on Antimalaria Efficacy and Drug Resistance: 2000-2010. Geneva: World Health Organization.

Trape J, 2001. The public Health Impact of Chloroquine Resistance in Africa. Am J Trop Med Hyg **64**-(1-2 Suppl): 12-17.